rs11045995 - IAPP, SLCO1A2

Magnitude 2.2 · 1 study on file

Reported associations

• First genome-wide association study on rocuronium dose requirements shows association with SLCO1A2 - Unknown journal (n.d.) · Unknown authors · PubMed 33676726

  ABSTRACT: Background Rocuronium, a common neuromuscular blocking agent, is mainly excreted unchanged in urine (10-25%) and bile (>70%). Age, sex, liver blood flow, smoking, medical conditions, and ethnic background can affect its pharmacological actions. However, reasons for the wide variation in rocuronium requirements are mostly unknown. We hypothesised that pharmacogenetic factors might explain part of the variation. Methods One thousand women undergoing surgery for breast cancer were studied. Anaesthesia was maintained with propofol (50-100 μg kg−1 min−1) and remifentanil (0.05-0.25 μg kg−1 min−1). Neuromuscular block was maintained with rocuronium to keep the train-of-four ratio at 0-10%. DNA was extracted from peripheral blood and genotyped with a next-generation ge

Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.